OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VIVS
VivoSim Labs, Inc.
There isn't enough reported data to score VIVS yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VIVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
VIVS's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VIVS PE Valuation
VIVS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VIVS Forward outlook
There aren't enough analyst estimates for VIVS to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over VIVS on earnings quality, reporting a profit while its opponent remains loss making.
VIVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.51 | -666% |
| Q2 2026 | -$4.46 | -$4.38 |
| Q1 2026 | -$5.35 | -$3.65 |
| Q4 2025 | $1.87 | +$11.95 |
| Q3 2025 | $0.62 | +$13.22 |
| Q2 2025 | -$0.08 | +$16.36 |
| Q1 2025 | -$1.70 | +$17.50 |
| Q4 2024 | -$10.08 | +$16.08 |
VIVS has swung to a loss: it lost $3.51 per share over the past year, after a profit the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VIVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VIVS on profitability, with a higher operating margin.
VIVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $51K | +82% |
| Q2 2026 | $18K | -51% |
| Q1 2026 | $40K | -22% |
| Q4 2025 | $26K | +8.3% |
| Q3 2025 | $28K | -6.7% |
| Q2 2025 | $37K | -5.1% |
| Q1 2025 | $51K | +76% |
| Q4 2024 | $24K | +380% |
VIVS's revenue is recovering but still below its 2019 peak: $51,000 last quarter, up 82% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6502% | +2909 points |
| Q2 2026 | -15328% | -7449 points |
| Q1 2026 | -7968% | -1783 points |
| Q4 2025 | -10577% | +3873 points |
| Q3 2025 | -9411% | -717 points |
| Q2 2025 | -7878% | +804 points |
| Q1 2025 | -6184% | +4492 points |
| Q4 2024 | -14450% | +59150 points |
VIVS's operating margin was −6502% last quarter, up 2909 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with VIVS at up 15%.
VIVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.2M | +$704K |
| Q1 2026 | -$2.2M | -$203K |
| Q4 2025 | -$2.3M | -$470K |
| Q2 2025 | -$3.9M | -$957K |
| Q1 2025 | -$2M | +$636K |
| Q4 2024 | -$1.8M | +$1.7M |
| Q3 2024 | -$2.7M | +$521K |
| Q2 2024 | -$3M | +$2.3M |
VIVS has burned cash in almost every quarter: −$10M over the past year, against −$10M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over VIVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VIVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +214% | +11.2M shares |
| 1 year | +557% | +13.9M shares |
| 3 years | +2165% | +15.7M shares |
| 5 years | +2777% | +15.9M shares |
| Available history | +2925% | +15.9M shares |
VIVS has 16M diluted shares, up 557% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VIVS Net Leverage
VIVS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VIVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.5 | Oversold |
| Stochastic | 3.0 | Oversold |
VIVS's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VIVS PE vs Healthcare Sector
| Metric | VIVS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIVS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VIVS on trend strength, trading above more of its moving averages.
VIVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 18% below |
| 20 week MA | $0.33 | 58% below |
| 50 week MA | $1.18 | 88% below |
| 100 week MA | $1.95 | 93% below |
| 200 week MA | $8.06 | 98% below |
VIVS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VIVS on returns for 2026, with the stronger performance.
VIVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $96.0 | $191.5 | +100% |
| 2021 | $191.5 | $48.2 | -75% |
| 2022 | $48.2 | $19.1 | -60% |
| 2023 | $19.1 | $13.3 | -30% |
| 2024 | $13.3 | $3.67 | -72% |
| 2025 | $3.67 | $2.01 | -45% |
| 2026 YTD | $2.01 | $0.14 | -93% |
VIVS has finished five years in a row lower, and it's down 93% so far in 2026.